EGFR and ovarian carcinoma: DNMT3A has been proven to be a risk factor for rectal cancer, blood cancer and ovarian cancer etc. A recent study on the side effects of immunotherapy found that EGFR and DNMT3A are associated with Hyper-progressors (Champiat et al., 2017; Kato et al., 2017).